EPHX1 enhances drug resistance to regorafenib by activating the JAK/STAT signaling pathway in hepatocellular carcinoma cell lines

EPHX1 enhances drug resistance to regorafenib by activating the JAK/STAT signaling pathway in hepatocellular carcinoma cell lines

Abstract Background Regorafenib serves as a second-line treatment for patients with advanced hepatocellular carcinoma (HCC). Microsomal epoxide hydrolase 1 (EPHX1) is closely associated with tumorigenesis and drug resistance. However, the relationship between EPHX1 and regorafenib resistance, as wel...

Full description

Saved in:
Bibliographic Details
Main Authors: Bin Xu, Xiangnan Liang, Wuguang Liu, BaiTong Wu, Qiuxiang Wang, Gong Kai, Chun Han, Binwen Sun, Bing Dong, Chengyong Dong, Liming Wang
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Hereditas
Subjects:
EPHX1
Hepatocellular carcinoma
Regorafenib
Drug resistance
JAK/STAT pathway
Online Access:https://doi.org/10.1186/s41065-025-00517-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s41065-025-00517-1

Similar Items